ERBB2 and breast carcinoma: Additionally, there were similar rates of HER2+ (56.9% vs 52.6%) and triple‐negative (41.7% vs 38.4%) subtypes, and a lower proportion of high‐risk HR+/HER2‐ breast cancers (1.4% vs 9.1%).